SUPERNUS PHARMACEUTICALS INC (SUPN) Stock Earnings & Estimates
USA - NASDAQ:SUPN - US8684591089 - Common Stock
50.17 USD
+0.41 (+0.82%)
50.35 USD
+0.18 (+0.36%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 667.2M 15.07% | 607.521M -8.94% | 661.817M 8.94% | 706.24M 6.71% | 845.65M 19.74% | 963.47M 13.93% | 1.092B 13.34% | 1.232B 12.82% | 1.244B 0.97% | 1.284B 3.22% | 1.334B 3.89% | |
| EBITDA YoY % growth | 131.6M -6.60% | 99.779M -24.18% | 170.98M 71.36% | 98.283M -42.52% | 154.75M 57.45% | 236.42M 52.78% | 365.77M 54.71% | 319.67M -12.60% | 284.17M -11.11% | 246.02M -13.43% | 277.03M 12.60% | |
| EBIT YoY % growth | 46.1M -57.43% | 14.92M -67.64% | 90.566M 507.01% | 124.42M 37.38% | 166.77M 34.04% | 259.98M 55.89% | 315.24M 21.26% | 486.44M 54.31% | 431.77M -11.24% | 473.59M 9.69% | 576.81M 21.80% | |
| Operating Margin | 6.91% | 2.46% | 13.68% | 17.62% | 19.72% | 26.98% | 28.87% | 39.48% | 34.71% | 36.88% | 43.24% | |
| EPS YoY % growth | 1.03 5.10% | 1.40 35.92% | 2.95 110.71% | 2.27 -23.13% | 2.49 9.60% | 3.90 56.77% | 5.41 38.74% | 6.89 27.36% | 6.17 -10.37% | 6.78 9.92% | 8.16 20.30% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.32 -72.97% | 0.63 -16.59% | 0.50 14.75% | 0.62 -30.87% | 0.59 87.10% | 0.73 17.39% |
| Revenue Q2Q % growth | 180.05M 2.48% | 208.57M 19.76% | 190.03M 26.84% | 202.13M 22.17% | 198.19M 10.07% | 209.66M 0.52% |
| EBITDA Q2Q % growth | 1.861M -98.18% | 40.125M -63.76% | 67.83M 569.79% | 72.93M 35.35% | 73.44M 3,846.27% | 81.6M 103.36% |
| EBIT Q2Q % growth | 19.775M -51.59% | 36.51M 20.48% | 31.671M 408.80% | 39.984M 229.33% | 44.268M 123.86% | 52.428M 43.60% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 0.90 16.88% | 0.48 | 0.42 | 87.73% |
| Q1 2025 Q2Q % growth | 0.44 69.23% | 0.38 | 0.06 | 15.55% |
| Q4 2024 Q2Q % growth | 0.75 -15.73% | 0.42 | 0.33 | 77.18% |
| Q3 2024 Q2Q % growth | 1.17 387.50% | 0.45 | 0.72 | 158.74% |
| Q2 2024 Q2Q % growth | 0.77 3,950.00% | 0.40 | 0.37 | 93.56% |
| Q1 2024 Q2Q % growth | 0.26 -10.34% | 0.38 | -0.12 | -32.33% |
| Q4 2023 Q2Q % growth | 0.89 106.98% | 0.56 | 0.33 | 57.69% |
| Q3 2023 Q2Q % growth | 0.24 700.00% | 0.08 | 0.16 | 194.12% |
| Q2 2023 Q2Q % growth | -0.02 -114.29% | 0.07 | -0.09 | -130.17% |
| Q1 2023 Q2Q % growth | 0.29 -32.56% | 0.17 | 0.12 | 67.24% |
| Q4 2022 Q2Q % growth | 0.43 975.00% | 0.69 | -0.26 | -38.00% |
| Q3 2022 Q2Q % growth | 0.03 -92.50% | 0.36 | -0.33 | -91.75% |
| Q2 2022 Q2Q % growth | 0.14 -67.44% | 0.30 | -0.16 | -52.67% |
| Q1 2022 Q2Q % growth | 0.43 290.91% | 0.24 | 0.19 | 75.65% |
| Q4 2021 Q2Q % growth | 0.04 -92.98% | 0.24 | -0.20 | -83.43% |
| Q3 2021 Q2Q % growth | 0.40 -45.95% | 0.24 | 0.16 | 68.67% |
| Q2 2021 Q2Q % growth | 0.43 -33.85% | 0.20 | 0.23 | 113.45% |
| Q1 2021 Q2Q % growth | 0.11 -72.50% | 0.25 | -0.14 | -55.53% |
| Q4 2020 Q2Q % growth | 0.57 -8.06% | 0.53 | 0.04 | 7.99% |
| Q3 2020 Q2Q % growth | 0.74 37.04% | 0.30 | 0.44 | 143.86% |
| Q2 2020 Q2Q % growth | 0.65 6.56% | 0.43 | 0.22 | 51.73% |
| Q1 2020 Q2Q % growth | 0.40 17.65% | 0.29 | 0.11 | 39.06% |
| Q4 2019 Q2Q % growth | 0.62 | 0.62 | 0.00 | 0.75% |
| Q3 2019 Q2Q % growth | 0.54 | 0.61 | -0.07 | -11.76% |
| Q2 2019 Q2Q % growth | 0.61 | 0.59 | 0.02 | 3.11% |
| Q1 2019 Q2Q % growth | 0.34 | 0.48 | -0.14 | -29.45% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 165.453M -1.71% | 157.14M | 8.313M | 5.29% |
| Q1 2025 Q2Q % growth | 149.824M 4.30% | 150.89M | -1.066M | -0.71% |
| Q4 2024 Q2Q % growth | 174.159M 5.99% | 158.36M | 15.799M | 9.98% |
| Q3 2024 Q2Q % growth | 175.689M 14.17% | 160.44M | 15.249M | 9.50% |
| Q2 2024 Q2Q % growth | 168.325M 24.17% | 151.83M | 16.495M | 10.86% |
| Q1 2024 Q2Q % growth | 143.644M -6.58% | 148.75M | -5.106M | -3.43% |
| Q4 2023 Q2Q % growth | 164.314M -1.78% | 158.13M | 6.184M | 3.91% |
| Q3 2023 Q2Q % growth | 153.88M -13.26% | 146.25M | 7.63M | 5.22% |
| Q2 2023 Q2Q % growth | 135.563M -20.30% | 146.53M | -10.967M | -7.48% |
| Q1 2023 Q2Q % growth | 153.764M 0.83% | 141.8M | 11.964M | 8.44% |
| Q4 2022 Q2Q % growth | 167.3M 5.15% | 183.98M | -16.68M | -9.07% |
| Q3 2022 Q2Q % growth | 177.4M 19.46% | 175.93M | 1.47M | 0.84% |
| Q2 2022 Q2Q % growth | 170.1M 20.38% | 167.51M | 2.59M | 1.55% |
| Q1 2022 Q2Q % growth | 152.5M 16.50% | 153.48M | -980K | -0.64% |
| Q4 2021 Q2Q % growth | 159.1M 10.79% | 155.77M | 3.33M | 2.14% |
| Q3 2021 Q2Q % growth | 148.5M -4.26% | 144.96M | 3.54M | 2.44% |
| Q2 2021 Q2Q % growth | 141.3M 11.52% | 137.57M | 3.73M | 2.71% |
| Q1 2021 Q2Q % growth | 130.9M 37.79% | 131.78M | -880K | -0.67% |
| Q4 2020 Q2Q % growth | 143.6M 43.03% | 149.11M | -5.51M | -3.70% |
| Q3 2020 Q2Q % growth | 155.1M 51.91% | 133.27M | 21.83M | 16.38% |
| Q2 2020 Q2Q % growth | 126.7M 21.01% | 100.06M | 26.64M | 26.62% |
| Q1 2020 Q2Q % growth | 95M 11.11% | 85.151M | 9.849M | 11.57% |
| Q4 2019 Q2Q % growth | 100.4M | 113.76M | -13.36M | -11.74% |
| Q3 2019 Q2Q % growth | 102.1M | 112.03M | -9.93M | -8.86% |
| Q2 2019 Q2Q % growth | 104.7M | 111.89M | -7.19M | -6.43% |
| Q1 2019 Q2Q % growth | 85.5M | 105.65M | -20.15M | -19.07% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 8.14% | -41.14% | 0% | 31.04% |
| Revenue | 0.4% | 10.49% | 0.4% | 8.18% |